Anticoagulants Market Size By Drug Class (Factor Xa Inhibitors, Heparin, Warfarin, Direct Thrombin Inhibitors), By Route of Administration (Oral, Injectables), By Application (Venous Thromboembolism, Atrial Fibrillation/Flutter, Coronary Artery Disease),

Anticoagulants Market Size By Drug Class (Factor Xa Inhibitors, Heparin, Warfarin, Direct Thrombin Inhibitors), By Route of Administration (Oral, Injectables), By Application (Venous Thromboembolism, Atrial Fibrillation/Flutter, Coronary Artery Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2030

The global anticoagulants market is set to witness robust growth through 2030 owing to the increasing geriatric population across the globe. In addition, surging prevalence of obesity is also expected to positively impact the market over the forecast timeframe.

The COVID-19 pandemic has been instrumental in boosting the production of blood thinners as people suffering from cardiac ailments were at a higher risk of contracting the infection because of low immunity. Furthermore, major players in the industry have been focusing on expanding their production capacity and implementing strategies to fortify their market position.

For instance, in December 2021, pharma giant Johnson & Johnson announced that the U.S. FDA had approved two of its pediatric indications for XARELTO. These drugs are designed for use in venous thromboembolism (VTE) treatment as well as to cut the risks of recurrent VTE in patients aged below 18 years.

The anticoagulants market has been divided by route of administration, distribution channel, drug category, application, and region.

Based on the drug category, the market has been bifurcated into factor Xa inhibitor, direct thrombin inhibitor, heparin, and warfarin (Vitamin K antagonist). Among these, the direct thrombin inhibitor segment accounted for more than 12.7% market share in 2021. These inhibitors function by slowing down the activity of the thrombin protein to delay the blood clotting process and are hence used to treat heparin-induced thrombocytopenia (HIT) and acute coronary syndrome.

On the basis of route of administration, the anticoagulants market has been categorized into injectables and oral. The injectables segment is set to witness robust growth over 2022-2030 backed by rising usage of injectables in various disease treatments.

With respect to application, the market has been divided into atrial fibrillation/flutter, coronary heart disease, and venous thromboembolism. The coronary heart disease segment will grow substantially up to 2030 owing to increasing heart-related problems resulting from consumers’ unhealthy lifestyle. In addition, increasing elderly population, who are more prone to cardiovascular disease, is likely to spur segmental adoption.

In the context of distribution channel, the anticoagulants market has been segregated into retail pharmacy, hospital pharmacy, and online pharmacy. In 2021, the hospital pharmacy segment captured a market share of nearly 53.8% and is foreseen to observe robust progress in the upcoming time period driven by the benefits of these pharmacies, such as easy availability of medicines. Moreover, growing patients’ preference for hospitals for their high quality care is expected to boost segmental growth.

In the regional context, the Middle East & Africa anticoagulants market was valued at more than USD 426.8 million in 2021 supported by the presence of a large patient pool in the MEA region. Meanwhile, the LATAM anticoagulants industry is anticipated to showcase a CAGR of around 8.9% through the forecast period. Improving healthcare infrastructure and growing demand for surgical procedures that require anticoagulant drugs are poised to fuel market development in Latin America.